Literature DB >> 32017058

The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity.

Colin D Godwin1,2, Olivia M Bates1, Eliotte E Garling1, Mary E Beddoe1, George S Laszlo1, Roland B Walter1,2,3,4.   

Abstract

Entities:  

Keywords:  Bruton’s tyrosine kinase; IL-2-inducible T-cell kinase; acute leukaemia; bispecific antibody; ibrutinib

Mesh：

Substances：

Year:  2020        PMID： 32017058      PMCID： PMC7103514          DOI： 10.1111/bjh.16406

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  15 in total

1.  Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia.

Authors:  Frederick Fasslrinner; Claudia Arndt; Stefanie Koristka; Anja Feldmann; Heidi Altmann; Malte von Bonin; Marc Schmitz; Martin Bornhäuser; Michael Bachmann
Journal:  Br J Haematol       Date:  2019-05-23       Impact factor: 6.998

2.  Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.

Authors:  M Ruella; S S Kenderian; O Shestova; M Klichinsky; J J Melenhorst; M A Wasik; S F Lacey; C H June; S Gill
Journal:  Leukemia       Date:  2016-09-28       Impact factor: 11.528

3.  Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation.

Authors:  Alan K Kutach; Armando G Villaseñor; Diana Lam; Charles Belunis; Cheryl Janson; Stephen Lok; Li-Na Hong; Chao-Min Liu; Jerome Deval; Thomas J Novak; Jim W Barnett; Wei Chu; David Shaw; Andreas Kuglstatter
Journal:  Chem Biol Drug Des       Date:  2010-06-09       Impact factor: 2.817

4.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Authors:  Jason A Dubovsky; Kyle A Beckwith; Gayathri Natarajan; Jennifer A Woyach; Samantha Jaglowski; Yiming Zhong; Joshua D Hessler; Ta-Ming Liu; Betty Y Chang; Karilyn M Larkin; Matthew R Stefanovski; Danielle L Chappell; Frank W Frissora; Lisa L Smith; Kelly A Smucker; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami Maddocks; Amy M Lehman; Richard Furman; Jeff Sharman; Anjali Mishra; Michael A Caligiuri; Abhay R Satoskar; Joseph J Buggy; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

Review 5.  Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

6.  SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling.

Authors:  R A Blake; M A Broome; X Liu; J Wu; M Gishizky; L Sun; S A Courtneidge
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

7.  Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Authors:  John C Byrd; Bonnie Harrington; Susan O'Brien; Jeffrey A Jones; Anna Schuh; Steve Devereux; Jorge Chaves; William G Wierda; Farrukh T Awan; Jennifer R Brown; Peter Hillmen; Deborah M Stephens; Paolo Ghia; Jacqueline C Barrientos; John M Pagel; Jennifer Woyach; Dave Johnson; Jane Huang; Xiaolin Wang; Allard Kaptein; Brian J Lannutti; Todd Covey; Maria Fardis; Jesse McGreivy; Ahmed Hamdy; Wayne Rothbaum; Raquel Izumi; Thomas G Diacovo; Amy J Johnson; Richard R Furman
Journal:  N Engl J Med       Date:  2015-12-07       Impact factor: 91.245

8.  The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.

Authors:  Marco Ruella; Saad S Kenderian; Olga Shestova; Joseph A Fraietta; Sohail Qayyum; Qian Zhang; Marcela V Maus; Xiaobin Liu; Selene Nunez-Cruz; Michael Klichinsky; Omkar U Kawalekar; Michael Milone; Simon F Lacey; Anthony Mato; Stephen J Schuster; Michael Kalos; Carl H June; Saar Gill; Mariusz A Wasik
Journal:  Clin Cancer Res       Date:  2016-01-27       Impact factor: 12.531

9.  Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Authors:  Joseph A Fraietta; Kyle A Beckwith; Prachi R Patel; Marco Ruella; Zhaohui Zheng; David M Barrett; Simon F Lacey; Jan Joseph Melenhorst; Shannon E McGettigan; Danielle R Cook; Changfeng Zhang; Jun Xu; Priscilla Do; Jessica Hulitt; Sagar B Kudchodkar; Alexandria P Cogdill; Saar Gill; David L Porter; Jennifer A Woyach; Meixiao Long; Amy J Johnson; Kami Maddocks; Natarajan Muthusamy; Bruce L Levine; Carl H June; John C Byrd; Marcela V Maus
Journal:  Blood       Date:  2016-01-26       Impact factor: 22.113

10.  A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.

Authors:  Hannah R Robinson; Junpeng Qi; Erika M Cook; Cydney Nichols; Eman L Dadashian; Chingiz Underbayev; Sarah E M Herman; Nakhle S Saba; Keyvan Keyvanfar; Clare Sun; Inhye E Ahn; Sivasubramanian Baskar; Christoph Rader; Adrian Wiestner
Journal:  Blood       Date:  2018-05-09       Impact factor: 22.113
View more
  1 in total

Review 1.  Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors.

Authors:  Gabrielle Leclercq; Nathalie Steinhoff; Hélène Haegel; Donata De Marco; Marina Bacac; Christian Klein
Journal:  Oncoimmunology       Date:  2022-06-01       Impact factor: 7.723
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.